Celltrion Reveals Data As It Rolls Out Higher-Strength Adalimumab
Presents One-Year Data From Phase III Trial For Yuflyma Rival To Humira
As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.
You may also be interested in...
Sandoz is looking to enter the European market for high-concentration adalimumab after announcing EMA acceptance of its filing for a 100mg/ml version of its Hyrimoz biosimilar. Celltrion and Stada/Alvotech already have higher-strength rivals to Humira available in Europe.
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.
Celltrion Healthcare was ultimately able to increase its revenue by 16.7%, with stronger growth expected in H2.